Clinuvel Pharmaceuticals (FRA:UR9) Common Stock : €104.13 Mil (As of Jun. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Common Stock?

Clinuvel Pharmaceuticals's quarterly common stock increased from Jun. 2023 (€94.07 Mil) to Dec. 2023 (€104.07 Mil) and increased from Dec. 2023 (€104.07 Mil) to Jun. 2024 (€104.13 Mil).

Clinuvel Pharmaceuticals's annual common stock declined from Jun. 2022 (€100.95 Mil) to Jun. 2023 (€94.07 Mil) but then increased from Jun. 2023 (€94.07 Mil) to Jun. 2024 (€104.13 Mil).

Clinuvel Pharmaceuticals Common Stock Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Common Stock Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Common Stock

Get a 7-Day Free Trial

93.06

96.36

100.95

94.07

104.13

Clinuvel Pharmaceuticals Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Common Stock	Get a 7-Day Free Trial															100.95	96.72	94.07	104.07	104.13

Clinuvel Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Clinuvel Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (FRA:UR9) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

CLVLY:USA CLVLF:USA UR9:Germany UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Clinuvel Pharmaceuticals Headlines

No Headlines